Imunexus' technology facilitates rapid, cost-effective, lower risk, generation of effective therapeutics by converting existing biologic-based drugs such as antibodies, enzymes and other proteins into bispecifics so that the original drug now has an additional therapeutic function.

Our technology has generated a number of potential products for the treatment of a number of serious diseases.